Preemptive treatment with two drugs for MRD-positive AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining two drugs, sorafenib and venetoclax, as a preemptive therapy to eliminate leftover leukemia cells (MRD) in people with AML who are in remission. The goal is to prevent the disease from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) and still have some leukemia cells left after treatment (MRD positive).
- Your leukemia is in remission (no signs of cancer in blood or bone marrow) except for the MRD.
- You do not have a rare subtype called acute promyelocytic leukemia (APL).
- Your liver and kidney function meet basic safety levels: bilirubin ≤ 35 μmol/L, AST/ALT < 2 times normal, creatinine ≤ 150 μmol/L.
- Your heart function is normal (ejection fraction ≥ 50%, and you are in NYHA class I or II).
- You have not had uncontrolled infections or severe graft-versus-host disease (GVHD) after a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.